Expert Opinion on Emerging Drugs

Papers
(The median citation count of Expert Opinion on Emerging Drugs is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
A review of phase II and III drugs for the treatment and management of endometriosis28
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder28
Emerging and traditional 5-α reductase inhibitors and androgen receptor antagonists for male androgenetic alopecia28
New drugs targeting calcitonin gene-related peptide for the management of migraines21
Emerging drugs for the treatment of acne: a review of phase 2 & 3 trials19
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?19
Evolving role of VIADISC for chronic low back and discogenic pain: a narrative review19
How can we prevent diarrhea induced by systemic treatments in oncological patients? An evaluation of phase II trials18
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?17
Future treatments for myelin oligodendrocyte glycoprotein antibody-associated disease: the clinical trial landscape16
Emerging drugs for the treatment of progressive familial intrahepatic cholestasis: a focus on phase II and III trials15
Emerging medicines to improve the basic defect in cystic fibrosis12
Existing and emerging therapies for the treatment of invasive candidiasis and candidemia12
Emerging injectable therapies for osteoarthritis12
Emerging biological treatments for asthma12
Newly emerging tyrosine kinase inhibitors for the treatment of neuroendocrine neoplasms11
Emerging drugs for the treatment of herpetic keratitis11
A review of emerging factor XI inhibitors11
Cannabinoid treatment for the symptoms of autism spectrum disorder10
Emerging treatment for Sjögren’s disease: a review of recent phase II and III trials10
Expert opinion on emerging drugs for lung chronic graft-versus-host disease9
Emerging monoclonal antibody therapies in the treatment of metastatic urothelial carcinoma8
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?8
Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials8
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder8
Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria8
Recent advances in immune-based approaches for the treatment of esophagogastric cancer7
Novel and emerging drugs for the treatment of Crohn’s disease: a review of phase II and III trials7
Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trials7
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion7
Emerging tyrosine kinase inhibitors for head and neck cancer7
Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis7
Correction7
Emerging antiviral therapies and drugs for the treatment of influenza7
Emerging drugs for the treatment of irritability associated with autism spectrum disorder7
How will tovorafenib change our treatment of pediatric low-grade glioma?7
The role of HER2-targeted therapy in urothelial carcinomas6
Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials6
Correction6
Emerging drugs for the treatment of hepatic fibrosis on nonalcoholic steatohepatitis6
Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials6
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results6
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma6
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis6
Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency5
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?5
What’s new on the horizon for polycystic ovarian syndrome? Exploring emerging drugs in phase II5
Emerging drugs in the treatment of chronic cough5
Emerging drugs for the treatment of inflammatory bowel disease5
Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia5
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma5
Current and emerging drug treatment strategies to tackle sickle cell anemia5
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma5
Emerging synthetic drugs for the treatment of diffuse large B-cell lymphoma5
Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa5
An update on emerging drugs for the treatment of idiopathic pulmonary fibrosis: a look towards 2023 and beyond4
Evaluating emerging drugs in phase II & III for the treatment of amyotrophic lateral sclerosis4
Aticaprant: (a κ-opioid receptor antagonist) for major depressive disorder4
Emerging drugs for the treatment of diabetic nephropathy4
Emerging drugs for the treatment of major depressive disorder4
Emerging drugs for the treatment of alopecia areata4
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E4
Emerging drugs for the treatment of type 1 diabetes mellitus: a review of phase 2 clinical trials4
Letter to the editor: ‘Emerging gene therapy products for RPGR-associated X-linked retinitis pigmentosa’4
0.047966957092285